Vogenx Inc Common Stock Cash Flow Conversion Efficiency
Vogenx Inc Common Stock cash flow conversion efficiency. Based on the latest financial reports, Vogenx Inc Common Stock (VOGX) has a cash flow conversion efficiency ratio of -0.015x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($27.14K) by net assets ($-1.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Vogenx Inc Common Stock (2024–2025)
Cash flow conversion efficiency of Vogenx Inc Common Stock from 2024 to 2025. This chart illustrates how Vogenx Inc Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Vogenx Inc Common Stock (VOGX) stock price for real-time trading data and today's change.
Vogenx Inc Common Stock Cash Flow Conversion Ratio Explained
Vogenx Inc Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Vogenx Inc Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vogenx Inc Common Stock ranked by their cash flow conversion efficiency. Also see VOGX market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
QST International
TWO:8349
|
0.030x |
|
EnviTec Biogas AG
XETRA:ETG
|
0.086x |
|
Sichuan Golden Summit Group Joint Stock Co Ltd
SHG:600678
|
0.063x |
|
Xperi Corp
NYSE:XPER
|
0.237x |
|
Silvia, Inc.
NASDAQ:SVIA
|
-0.043x |
|
Tredegar Corporation
NYSE:TG
|
0.009x |
|
CERRO DE PASCO RES
F:N8HP
|
-0.043x |
|
PharmaEngine
TWO:4162
|
0.011x |
Annual Cash Flow Conversion Efficiency for Vogenx Inc Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Vogenx Inc Common Stock from 2024 to 2025. Review VOGX cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-919.24K | $-1.11 Million | 1.210x | +126.33% |
| 2024-12-31 | $509.58K | $-2.34 Million | -4.595x | -- |
About Vogenx Inc Common Stock
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party pay… Read more